Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

(2014) Xinghao Ai et al.   AMINO ACIDS

Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2

(2013) B. N. Rexer et al.   CLINICAL CANCER RESEARCH

Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients

(2012) T Doi et al.   BRITISH JOURNAL OF CANCER

Cannabinoids: A new hope for breast cancer therapy?

(2012) María M. Caffarel et al.   CANCER TREATMENT REVIEWS

Specific Noncovalent Interactions at Protein-Ligand Interface: Implications for Rational Drug Design

(2012) P. Zhou et al.   CURRENT MEDICINAL CHEMISTRY

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

(2012) J. De Grève et al.   LUNG CANCER

Free Energy Calculations by the Molecular Mechanics Poisson−Boltzmann Surface Area Method

(2012) Nadine Homeyer et al.   Molecular Informatics

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

(2011) Rama Krishna Kancha et al.   PLoS One

Improved prediction of protein side-chain conformations with SCWRL4

(2009) Georgii G. Krivov et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA